WuXi Biologics (HK:2269), a China-based global Contract Research, Development, and Manufacturing Organisation (CRDMO), announced on Wednesday that three of its manufacturing facilities in Wuxi – MFG1, MFG2, and DP5 – have received GMP certification from Turkish health regulator TITCK.

This marks the first GMP inspection conducted by Turkey's TITCK at WuXi Biologics. During the five-day onsite inspection of two monoclonal antibody biologics produced by WuXi Biologics for its clients, the three manufacturing facilities successfully passed TITCK's comprehensive assessment. All these facilities have previously received approval from other major regulatory authorities for the development of multiple biologic therapeutics.

As of the end of June 2025, Wuxi has successfully passed 44 regulatory inspections, including 22 conducted by the FDA and the EMA.